Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours By Ogkologos - February 10, 2026 299 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRIDENT-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR The Frontline Oncology Workforce Unites to Reduce the Burden of Cancer... September 9, 2022 Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with... April 26, 2022 Targeted drug recommended to treat some advanced lung cancer patients November 25, 2021 Black Women Have Nearly Three Times the Risk of Developing Triple... September 22, 2021 Load more HOT NEWS Taking on the RAS Challenge Self-Dissolving Cracker Makes Swallowing Easier for People Struggling with Dysphagia Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma... FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer
